Navigation Links
HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference
Date:3/7/2011

FRAMINGHAM, Mass. and SYDNEY, March 7, 2011 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Barclays Capital 2011 Global Healthcare Conference at 8:00 a.m. Eastern Time on Tuesday, March 15, 2011. The conference is being held March 15-17, 2011 at the Loews Miami Hotel, Florida.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time for a period of 90 days.

About HeartWare InternationalHeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.For further information:Christopher TaylorHeartWare International, Inc.Email: ctaylor@heartwareinc.comPhone: +1 508 739 0864
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
2. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
3. HeartWare to Present at the 29th Annual J.P. Morgan Healthcare Conference
4. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
5. HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
6. HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
7. HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock
8. HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
9. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
10. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
11. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/8/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed ... a health care service center company based in ... in relationship management programs for leading pharmaceutical manufacturers and ... WRB will join Envoy Health Management, LLC ... manufacturers, biotech firms, and other service companies. Together, WRB ...
(Date:5/4/2017)... 4, 2017  Fortuna Fix Inc. (" Fortuna "), ... first to eliminate the need for embryonic and fetal stem ... neurodegenerative diseases. Fortuna announced today the ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald , ... and Professor James Giordano , PhD. "We ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a ... creation of published author Laura Weigel Douglas, an avid reader who lives in the ... that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. , ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring ... School District had left education officials with a number of critical issues to address ... flooring had to be accomplished with little or no disruption to class schedules. Second, ...
(Date:5/24/2017)... San Diego, California (PRWEB) , ... May 24, ... ... patient care through innovative medical image management and interpretation, has received U.S. Food ... technology. , Nucleus.io is a web-based, scalable and secure cloud platform for ...
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well known for auctioning homes ... luxury homes anywhere on the planet. The luxury home market is alive and well ... city-scapes. A quick search of “11 Spyglass Hill Auction will enlighten you on the ...
Breaking Medicine News(10 mins):